The money from the Gates Foundation, Novo Nordisk Foundation, and Wellcome has been awarded to researchers in 17 countries.

But a new antibiotic from Swiss pharmaceutical company Roche could change the future of how we treat Gram-negative bacteria. Roche announced on Monday that its antibiotic zosurabalpin will enter phase ...

Scientists at Duke University report they have developed a synthetic antibiotic that could be effective against drug-resistant superbugs and bacteria such as Salmonella, Pseudomonas, and E. coli.

Munich, Germany, Jan. 20, 2026 (GLOBE NEWSWIRE) -- smartbax, a biotech company developing next-generation antibiotics against multi-drug ...

The Gates Foundation, Novo Nordisk Foundation, and Wellcome today awarded a total of $60 million in new grant funding over the next three years to research teams around the world exploring novel ...

Scientists in Switzerland have announced the discovery of a new class of antibiotics shown to be effective against deadly, drug-resistant bacteria. The antibiotic, called zosurabalpin, works by ...

Physicians have relied on a class of antibiotics called polymyxins to fight potentially life-threatening Gram-negative bacterial infections for more than 80 years. These drugs are typically reserved ...

Antibiotics kill disease-causing bacteria as well as the beneficial ones living in our gut, disturbing the health-maintaining microbiome. A new antibiotic specifically targets hard-to-kill bacteria ...

Animals house thousands of commensal bacterial species in their guts, which play an important role in maintaining the host’s health. 1 However, antibiotic treatment indiscriminately wipes out both ...

Munich-based smartbax, a biotech developing antibiotics against multi-drug resistant bacteria, has announced the in-licensing ...